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COMPLEMENT activation  during  extracorporeal  mem-
brane  oxygenation  (ECMO)  in  newborns  can  be
caused by both the underlying disease processes and
by blood contact with the ECMO circuit. We investi-
gated the relative importance of these mechanisms by
measuring C3a, C5a and sC5b-9 before, during and
after  neonatal  ECMO  in  six  consecutive  newborn
patients using enzyme-linked immunoassay. In addi-
tion  complement  activation  during  in  vitro ECMO
with repeated flow of  the  same  blood  volume  was
measured using blood from healthy adult donors. C3a
increased significantly in vivo after 1h (from 1035 ±
193 to 1865 ± 419m g/l) and in vitro ECMO (from 314
± 75 to 1962 ± 1062m g/l). C5a increased during ECMO
without significant differences between in vivo and in
vitro activation.  In  neonatal  patients,  sC5b-9  rose
faster than in vitro, but the rapid increase was also
significant for in vitro experiments (in vivo: from 328
± 63 to 1623 ± 387m g/l after 2h; and in vitro: from 78
± 32 to 453 ± 179m g/l after 8h). After this initial peak
at 1–2h, complement activation decreased gradually
until  2–3  days  after  the  initiation  of  ECMO.  We
conclude that in newborns the rapid activation of the
complement system  after the start of ECMO is pre-
dominantly caused by contact with artificial surfaces
rather than the patient’s underlying disease.
Key  words:  Neonate,  ECMO,  Complement  activation,
Artificial surfaces
Introduction
Extracorporeal membrane oxygenation (ECMO)  has
become standard treatment for newborn infants with
severe neonatal respiratory failure not responding to
conventional  pulmonary  support.1 Since  the  first
successful ECMO treatment in 1971, more then 10,000
babies have been treated world-wide with ECMO, with
an  improved  survival  and  a  favourable  outcome
compared with conventional treatment.2Additionally,
ECMO  is  used  for  temporary  circulatory  assist  in
children with heart failure awaiting transplantation.3
During ECMO, circulating plasma levels of inflam-
matory  mediators  and  neutrophil  activation
increase.4,5 This  generalized  inflammatory  reaction
contributes  to  the  capillary  leak  syndrome  and
pulmonary  oedema  observed  during  ECMO  ther-
apy.6–9 A major mechanism triggering this inflamma-
tory  reaction  is  the  activation  of  complement  by
contact of  blood  with  the  surface  of  the  synthetic
tubing  and  the  oxygenator.  Complement  activation
has  also  been  described  during  cardiopulmonary
bypass and the apheresis technique.10–12 In contrast
to cardiopulmonary bypass, which lasts only for a few
hours  and  is  combined  with  deep  hypothermia,
ECMO lasts for several days, is performed at normal
temperature and the patient sometimes has systemic
infection.
The aims of the present study were to investigate
the relative contribution of primary disease, contact
with the ECMO circuit, and infection to the comple-
ment activation during neonatal ECMO.
Patients and methods
In vivo neonatal ECMO
The study was approved by the institutional review
board and written parental consent was obtained for
each patient. During the study period, six newborns
requiring  ECMO  for  cardiorespiratory  failure  unre-
sponsive to conventional mechanical ventilation were
included in this prospective study.
The total volume of the ECMO circuit was 434 ±
8ml. The ECMO circuit was primed by the introduc-
tion of carbon dioxide, 0.9% saline solution contain-
ing 0.5IU of heparin/ml of solution and 5% albumin
containing 0.25 of IU heparin/ml of albumin.
After the priming procedure, the circuit was filled
with  type-specific,  cross-matched,  cytomegalovirus
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age). Tris buffer and calcium gluconate were added to
ensure pH 7.4 and a serum Ca of 2.4mmol/l. Then
100U of heparin was added to the circuit. All patients
were placed on veno-arterial ECMO. The right com-
mon carotid artery and jugular vein were cannulated.
All  patients  had  surveillance  blood  cultures  daily.
Anticoagulation  was  achieved  with  a  continuous
infusion  of  heparin  administered  into  the  venous
tubing of the circuit. Bedside monitoring of hepariniza-
tion was performed hourly by measuring the activated
clotting time (ACT). The target ACT was 180–200sec.
In vitro ECMO experiments
The same ECMO system used in the clinical situation
was used for in vitro experiments. After priming of
the ECMO circuit with carbon dioxide, saline solution
and albumin (as already described), the circuit was
filled with fresh human citrated phosphate dextrose
(CPD) blood, collected from healthy adult donors by
venipuncture. Heparin was added (300IU/l). In vitro
ECMO was performed at a constant temperature of
37°C  and  a  constant  flow  rate  of  300ml/min.  An
appropriate mixture of oxygen, nitrogen and carbon
dioxide was supplied to the membrane oxygenator to
keep blood gases in physiologic ranges. Electrolytes,
pH,  and glucose were kept constant in the physio-
logical range during the 8h of the experiments. For
further studies, cells and plasma were separated by
centrifugation.  A  total  of  six  independent  experi-
ments were performed.
Analytical methods
Blood samples for complement analysis were drawn
after  filling  the  ECMO  circuit  (0min),  and  15min,
30min, 1h, 2h, 4h, 8h (endpoint of in vitro ECMO),
16h, 32h, and 64h after initiation of ECMO, and 12h
after decanulation from ECMO. They were collected
in tubes containing ethylenediamine tetraacetic acid.
Within 10min of collection, the samples were cen-
trifuged  for  3min  at  3000rpm.  Plasma  was  imme-
diately separated and stored at –80°C.
Measurement of complement factors C3a, C5a,
sC5b-9:
The concentrations of the complement factors C3a,
C5a  and  sC5b-9  were  measured  in  duplicate  as
previously described.10,11,13The bioassays were blin-
ded for  group  assignment  and  clinical  data. A  C3a
enzyme-linked  immunoassay  (EIA)  (Progen  Biotech-
nik, Inc., Heidelberg, Germany) detected the comple-
ment  component  C3a-desArg  using  highly  selected
monoclonal antibodies. C5a was determined with a
specific  sandwich  EIA  (Aventis-Behring,  Marburg,
Germany).  Soluble  terminal  complement  complex
sC5b-9  was  measured  with  an  EIA  (LD  Labour
Diagnostika, Heiden, Germany). The accuracy of all
methods  used  was  assessed.  Within-run  precision
study  (n =  20)  of  all  methods used showed coeffi-
cients of variation between 4 and 9%.
Statistical analysis
All results are expressed as mean ± standard error of
the  mean.  Changes  in  the  concentrations  of  the
measured parameters with time were compared with
analysis of variance (Friedman analysis). Differences
between  the  neonatal  and  in  vitro ECMO  were
assessed  by  the  Mann–Whitney  U  test.  Statistical
significance was assumed at p < 0.05. All calculations
and  tests  were  performed  with  SPSS-PC  software
(Chicago, IL, USA).
Results
The patients’ clinical data and ECMO characteristics
are presented in Table 1. ECMO was started at a mean
age  of  147h  after  birth  and  the  mean  duration  of
ECMO  was  152h.  Using  a  neonatal  sepsis  score,14
three newborns were diagnosed with infection at the
initiation of ECMO according to the clinical situation
and laboratory infection values (immature:total ratio
of  neutrophils  >  20%,  thrombopenia,  leukopenia,
CrP  >  2mg/dl).  All  patients  received  ampicillin
(150mg/kg/day),  cefotaxime  (100mg/kg/day)  and
tobramycin or gentamicin (5mg/kg/day) prior to the
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Table 1. Clinical data of six newborns undergoing ECMO treatment for severe respiratory failure
Patient
number
Weeks of
gestation
Birth
weight
(g)
Sex Primary diagnosis Secondary
sepsis
Start of
ECMO
(h)
Time on
ECMO
(h)
Outcome
1 38 + 3 3260 Male Pneumonia, PPHN No 19 82 Survived
2 35 + 0 2760 Male Pneumonia Yes 56 165 Died after ECMO
3 40 + 0 3025 Female MAS Yes 160 120 Survived
4 41 + 6 4770 Male MAS, group B
streptococcus sepsis
No 264 179 Survived
5 38 + 0 3650 Female PPHN No 48 137 Survived
6 39 + 5 3130 Male PPHN No 334 228 Survived
MAS, Meconium aspiration syndrome; PPHN, persistent pulmonary hypertension of the newborn.ECMO  course,  and  antibiotic  treatment  was  con-
tinued during the course of ECMO treatment. Blood
cultures  were positive only  in  one  case (patient 4,
group  B  streptococcus). Following  deterioration of
the clinical status and changes in infection values at
day 3 of the course of ECMO, the antibiotic regime
was changed in  two out of six  newborn  babies to
vancomycin and imipenem  (patients 2  and  3),  and
secondary sepsis was diagnosed using  the neonatal
sepsis  score.14 A  causative agent  for  the secondary
sepsis was not detected in blood cultures drawn daily
under ECMO treatment.
All complement indices increased during in vivo
and in vitro ECMO (Figs 1–3).
C3a increased significantly within the first hour of
in  vivo and  in  vitro ECMO  experiments.  Baseline
values in vivo were higher than those in vitro (p =
0.02 for start and 15min) but the C3a increase was
more  pronounced  with  in  vitro ECMO.  Between
30min  and  8h,  C3a  concentrations  did  not  differ
significantly from in vivo and in vitro experiments.
In vivo ECMO C3a peaked after 1h (Fig. 1).
C5a concentrations also increased steadily during
in vitro ECMO. During in vivo ECMO there was an
increase  of  C5a  over  time,  with  a  peak  after  2h.
During the 8h, no significant differences were found
between in vivo and in vitro ECMO (Fig. 2).
The  sC5b-9  complex  concentration  increased  in
both in vitro (p = 0.02) and neonatal in vivo (p <
0.001) ECMO, with higher baseline values in neonatal
ECMO. In vitro, the terminal complement complex
was lower after filling the ECMO circuit and through-
out 8h of ECMO. In vivo, sC5b-9 increased after only
15min of  ECMO and was maximal at 2h of ECMO
(Fig. 3).
A second increase of C5a and sC5b-9 after 32h was
mainly  due  to  patients  2  and  3,  who  developed
symptoms of secondary sepsis at this time (Table 1).
They had an increased immature to total neutrophil
ratio, an increase of C-reactive protein, plus clinical
deterioration with signs of an infection. Patient 2 also
had leukocytosis. This  was  reflected by  an  intense
increase of  C5a concentration after 64h to 33  and
33.5mg/l  in  patients  2  and  3,  respectively. Twelve
hours  after  decanulation  of  the  ECMO  circulation,
C5a  remained  elevated  in  both  secondary-infected
patients (27.5  and 45mg/l). The other four patients
showed a decrease of C5a. This was also true for the
sC5b-9 concentration, where a comparable increase
in the secondary-infected patients was observed. In
patient 2 (after 32h, 892ng/ml; after 64h, 3510ng/
ml; 12h after decannulation, 3660ng/ml) and patient
3 (after 32h, 1630ng/ml; after 64h, 1920ng/ml; 12h
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FIG. 1. C3a concentration (mean ± SEM) in in vivo neonatal
ECMO and in in vitro ECMO (n = 6 for both groups). At 0h
and 0.25h, C3a is different in neonatal and in vitro ECMO (*p
<  0.05 by  Mann–Whitney U  test).  Both  groups  show  sig-
nificant  changes  with  time  during  the  observation period
(Friedman variance analysis). Post, 12h after decanulation.
FIG. 2. C5a concentration (mean ± SEM) in in vivo neonatal
ECMO and in in vitro ECMO (n = 6 for both groups). Both
groups  show  significant  changes  with  time  during  the
observation  period  (Friedman  variance  analysis)  but  no
difference  between  both  groups.  Post,  12h  after
decanulation.
FIG.  3.  sC5b-9  concentration  (mean  ±  SEM)  of  in  vivo
neonatal ECMO and in vitro ECMO (n = 6 for both groups). In
neonatal in vivo ECMO, sC5b-9 is higher compared with the
in vitro situation (*p < 0.05 by Mann–Whitney U test). Both
groups demonstrate a significant increase during the obser-
vation period (Friedman variance analysis). Post, 12h after
decanulation.after  decannulation  2800  ng/ml),  an  increase  was
observed,  whereas  the  other  patients  remained
unchanged (Fig. 4).
Discussion
Our study demonstrates complement activation dur-
ing  neonatal  ECMO  (Figs  1–3)  with  a  similar  time
course compared with adults. The complement sys-
tem  is  similarly  activated  during  cardiopulmonary
bypass, hemodialysis, and plasmapheresis by contact
with  artificial  membranes  via  the  alternative  path-
way.12 The  peak of activation was  reached for C3a
after 1h and for C5a and sC5b-9 after 2h, in analogy
to  the  results  of Vallhonrat  et  al. in  adults.12 The
stronger binding of C5a to the complement receptors
could explain  the delayed course of  C5a activation
compared with C3a activation.15 In  contrast to the
results of Vallhonrat et al. in two adults, the sC5b-9
values of the investigated six neonates did not decline
to  the  beginning  values  after  2  days.  Only  C3a
concentrations decreased after the initial peak at 1h
to values similar to the initial value at 24h, confirming
the results of Hocker et al.4 and Pl¨ otz et al.7
Concentrations of C5a and sC5b-9 showed a second
increase at  64h due to  secondary infection  of  two
newborns during ECMO, with extremely high values
for sC5b-9 and C5a. Secondary infections during ECMO
can be favoured by elevated endotoxin levels after 36h
of  ECMO.16 But  even  for  the  four  infants  without
secondary infection, concentrations of sC5b-9 remain
elevated (Fig. 4). Obviously, the complement activation
in  neonates  persists  longer  than  in  adults.  The
difference in time patterns of the activation products
during neonatal ECMO corresponded to the reaction
pattern of the clotting system in neonatal ECMO, where
some  activation  products  were  normalized  after  an
initial increase, such as thrombin–antithrombin com-
plexes.  Other  products  persisted  on  a  higher  level
during the whole course of the membrane oxygenation
procedure, such as D-dimer.7,17
A comparison of complement activation between
neonatal and in vitro ECMO is especially suitable for
determining which part of complement activation is
caused by the extracorporeal circuit and which part by
patients’ underlying  disease and their treatment. In
neonatal in vivoECMO, higher initial values of C3a and
sC5b-9  indicate  a  mild  complement  activation  in
patients at the start of ECMO, corresponding to the
results of Pl¨ otz et al.7Suitable to this finding, Wagner et
al.18 reported a  complement  activation in  pre-term
infants with respiratory distress syndrome. The differ-
ences  between  neonatal  and  in  vitro ECMO  were
balanced  for  C3a  and  C5a  at  1h  by  a  powerful
complement activation after the start of ECMO. The
simultaneous rise of anaphylatoxin concentration in
neonatal and in vitro ECMO indicate that this part of
complement activation is independent of interaction
with endothelium or tissue. In vitro the anaphylatoxin
concentration increased steadily, whereas in neonates
concentrations peaked after 1h for C3a and after 2h
for C5a. This difference could be caused by an in vivo
suppression of the complement activation process due
to  increased  production  of  complement  inhibitors
during ECMO or by reduced clearance of anaphylatox-
ins in the in vitro ECMO situation. In vivo, desArg-
forms of anaphylatoxins are hepatically metabolized.
The marked quantitative difference of sC5b-9 con-
centrations between neonatal and in vitro ECMO is
mainly due to the different blood used. In neonatal
ECMO only  heparin was added to prevent coagula-
tion, but in in vitro ECMO CPD blood was used with
additional  heparin.  This  can  inhibit  the  terminal
complement pathway with a lower amount of sC5b-9
produced in  in vitro ECMO.  Beyond that, different
sample characteristics of citrated and heparin blood
in the EIA can disturb the determination of sC5b-9. We
speculate that it is also possible that the activation of
the  terminal  complement  pathway  is  due  to  the
interaction with the in vivo system (e.g. the produc-
tion  of  complement  proteins  C6-C9  in  the  liver  or
other cells after initial complement activation).
The  observed  anaphylatoxins  and  the  terminal
complement complex promote neutrophil and mono-
cyte activation, chemotaxis, the production of various
cytokines, histamine release from basophils and mast
cells, contraction of smooth muscle cells and aggrega-
tion of platelets, and therefore increase morbidity with
capillary leakage syndrome, which was often observed
in neonatal ECMO.8,19 The decrease of complement
activation  by  inhibiting  drugs  or  improved  circuits
with  higher  biocompatibility  may  be  beneficial  for
newborn patients on ECMO.7,19,20Our in vitro ECMO
model  showed  similar  activation  of  C3a  and  C5a,
which resembles the in vivo situation.
In summary, the complement system in newborns
is rapidly activated by ECMO. After an initial peak of
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FIG.  4.  Mean  sC5b-9  concentration  of  neonates  without
secondary infection during ECMO (d , patients 1, 4, 5, and 6)
and in neonates with secondary infection during ECMO (x,
patients 2 and 3). Post, 12h after decanulation.complement activation products at 1–2h, a gradual
decrease of complement activation products occurs
until 2–3 days with ECMO. The rapid initial increase is
caused predominantly by the contact with artificial
surfaces and is not an effect of the patients underlying
disease. The in vitro model closely resembles the in
vivo situation  and  can  therefore  be  used  to  test
strategies  to  attenuate  complement  activation  by
improving  ECMO  with  more  inert  extracorporeal
material or complement activation inhibiting drugs.
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